- MVD and primary PCI: which strategy?
- 'The Great Debate' - Dual antiplatelet therapy - Which drug? For which patient? For which stent? For how long?
- 'The Great Debate' - Diffuse Coronary artery disease - Available options? New strategies on the Horizon? How to best optimise the options?
- Is what you see really what you get?
- FFR assessment of coronary stenoses in series
- EuroIntervention First Impact Factor - 3.285
EuroIntervention First Impact Factor - 3.285
Although the Impact Factor (IF) was created in 1955 for a world without faxes, computers, smartphones or the Internet, it is still recognised today as a critical and very academic parameter of scientific assessment. In the life of a scientific journal, the first milestone is to be recognised and indexed by Pubmed, the second is to have your official IF determined.
EuroIntervention took an unusual strategy, instead of requesting the IF immediately, we choose to wait just a little longer before applying so that we could benefit from the extra exposure and momentum gained after our early years of existence, and thus hope for a higher first IF. The result of this strategy has been better than expected - very close to 3.3 - which puts us in an excellent position with respect to our “so-called” long-term competitors.
While this is the end of the beginning for us, since we have received our “Lettre de Noblesse”, there is still a long way to go before we can aspire to joining the ranks of the European Heart Journal or the other, US based, cardiology journals. At the present, what is unknown is whether journals dealing with percutaneous interventions remain in the 2- 5 IF range or progress beyond this level.
On the other hand, we would like to reiterate our wish for an upgrade or update of the IF itself. It is clear today in a world with eblasts, iPads and instant downloads, not to mention Facebook and Twitter, that 57 years after its inception, the IF should be rejuvenated and readjusted to reflect our changing world.
Finally, on a personal note, I would like to sincerely thank the authors who submitted their work and bestowed their trust in EuroIntervention in the non-IF period, and to the many reviewers who gave us their time and effort without any tangible reward but the desire to further the work of our European science. On behalf of our team, we look forward to carrying on the work with both authors and reviewers, which now, in this bright and promising IF period will undoubtedly entail even more submissions and review work.
Patrick W. Serruys |
2011 Journal Citation Reports (R) (Thomson Reuters, 2011)